Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone-sensitive Prostate Cancer (mHSPC)”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05717582
What this trial is testing

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Who this might be right for
Metastatic Prostate CancerCastration-Sensitive Prostate Cancer
Fudan University 47
Large-scale testing (Phase 3)Active Not RecruitingNCT05288166
What this trial is testing

Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Who this might be right for
Prostatic NeoplasmsNeoplasm MetastasisUrogenital Neoplasms+14 more
Eli Lilly and Company 925
Testing effectiveness (Phase 2)Study completedNCT06312670
What this trial is testing

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma
Pedro Barata, MD, MSc 13
Not applicableUnknownNCT05530395
What this trial is testing

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Who this might be right for
Prostate Cancer Metastatic
Ignacio Puche Sanz 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05059236
What this trial is testing

Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 223
Testing effectiveness (Phase 2)Looking for participantsNCT07216248
What this trial is testing

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
University of Utah 160
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04925063
What this trial is testing

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Who this might be right for
Metastatic Prostate Cancer
Sun Yat-sen University 266
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Not applicableLooking for participantsNCT05649943
What this trial is testing

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 566
Not applicableLooking for participantsNCT06446401
What this trial is testing

The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Uppsala University 1,400
Large-scale testing (Phase 3)Study completedNCT02677896
What this trial is testing

Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 1,150
Post-approval studies (Phase 4)Active Not RecruitingNCT06479187
What this trial is testing

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Brigham and Women's Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT07241416
What this trial is testing

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd. 156
Not applicableLooking for participantsNCT07172685
What this trial is testing

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Who this might be right for
Prostate Cancer
Qilu Hospital of Shandong University 116
Not applicableStudy completedNCT07086651
What this trial is testing

Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate Neoplasms+1 more
Pfizer 1,300
Testing effectiveness (Phase 2)WithdrawnNCT03343977
What this trial is testing

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Peng Wang, MD PhD
Not applicableLooking for participantsNCT06661122
What this trial is testing

Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer 100
Load More Results